blue cross glp 1 coverage GLP-1 Blue Cross Blue Shield of

The acquisition provided Roche with three clinical-stage assets with potential in treating obesity and diabetes: as previously mentioned, CT-996, a once-daily oral small-molecule GLP-1 receptor agonist for treating obesity in patients with and without Type 2 diabetes, as well as two injectable clinical drug candidates: CT-388, a once-weekly subcutaneous injectable for treating obesity in patients with and without Type 2 diabetes, and CT-868, a once-daily subcutaneous injectable, for treating Type 1 diabetes patients with overweight or obesity

In addition, clinicians now have more flexibility when tailoring treatment plans

He noted that many people are more comfortable with taking a pill than sticking themselves with a needle

GLP-1 usage will continue to influence consumer food demand and prompt food manufacturers and retailers to adapt by introducing products tailored to health-conscious consumers who focus on portion-controlled meals and nutrient-rich options

++ represent significance compared to placebo

Book your consultation with a MEDvidi healthcare professional to learn more about starting your online weight loss journey and get guidance along the way